Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

• Nadine Kutsch,
• Christian Pallasch,
• Eugen Tausch,
• Volkmar Böhme,
• Matthias Ritgen,
• Rüdiger Liersch,
• Alexander Wacker,
• Georg Jacobs,
• Ralf Ulrich Trappe,
• Peter Dreger,
• Kirsten Fischer,
• Anna-Maria Fink,
• Stephan Stilgenbauer,
• Shuyan Zhai,
• Biao Li,
• Juliane M. Jürgensmeier,
• Nishanthan Rajakumaraswamy,
• Pankaj Bhargava,
• Michael Hallek,
• Barbara F. Eichhorst

Affiliations

Nadine Kutsch

1 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany

Christian Pallasch

2 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Germany

Eugen Tausch

3 Department of Internal Medicine III, Ulm University, Ulm, Germany

Volkmar Böhme

4 Oncology Lerchenfeld Clinic, Hamburg, Germany

Matthias Ritgen

5 Department of Medicine II, University of Schleswig-Holstein, Kiel, Germany

Rüdiger Liersch

6 Gemeinschaftspraxis für Hämatologie und Onkologie, Clemenshospital Münster, Düesbergweg, Germany

Alexander Wacker

7 Department of Internal Medicine I, Klinikum am Steinenberg, Reutlingen, Germany

Georg Jacobs

8 Praxis Fuer Onkologie, Saarbrücken, Germany

Ralf Ulrich Trappe

9 Department of Hematology and Oncology, DIAKO Hospital Bremen, Germany

Peter Dreger

10 Department of Medicine V, University Hospital Heidelberg, Germany

Kirsten Fischer

1 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany

Anna-Maria Fink

1 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany

Stephan Stilgenbauer

3 Department of Internal Medicine III, Ulm University, Ulm, Germany

Shuyan Zhai

11 Gilead Sciences, Inc., Foster City, California, USA

Biao Li

11 Gilead Sciences, Inc., Foster City, California, USA

Juliane M. Jürgensmeier

11 Gilead Sciences, Inc., Foster City, California, USA

Nishanthan Rajakumaraswamy

11 Gilead Sciences, Inc., Foster City, California, USA

Pankaj Bhargava

11 Gilead Sciences, Inc., Foster City, California, USA

Michael Hallek

1 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany

Barbara F. Eichhorst

1 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany